Will Editas Medicine stock go up or down?
Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.
Should you invest in edit shares?
Apr 22, 2022 · Editas Medicine Inc. NASDAQ Updated Apr 22, 2022 11:59 PM EDIT 14.59 0.22 (1.53%). Post-Market 0.40 (2.74%)
What is the edit stock price prediction for 2026-12-04?
Apr 24, 2022 · finance.yahoo.com - March 1 at 5:31 PM. Editas Medicine (NASDAQ:EDIT) adds US$129m to market cap in the past 7 days, though investors from a year ago are still down 61%. finance.yahoo.com - February 28 at 9:12 AM. SVB Leerink Maintains Market Perform on Editas Medicine, Lowers Price Target to $27.
How can I get the latest news and ratings for edit?
Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business.
Will edit stock go up?
A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top....Predicted Opening Price for Editas Medicine, Inc of Monday, April 25, 2022.Fair opening price April 25, 2022Current price$14.63$14.60 (Undervalued)
Is edit stock a buy?
The consensus among 8 Wall Street analysts covering (NASDAQ: EDIT) stock is to Buy EDIT stock.
Is edit a buy or sell?
The median P/B ratio for stocks in the S&P is just over 3....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Why is edit stock down?
The stock price of Editas plunged 19% in yesterday's trading session after the company shared interim data for its EDIT 101 - a CRISPR-based treatment for Leber congenital amaurosis.Oct 1, 2021
Where is Editas Medicine located?
Cambridge, MAEditas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases. Our corporate headquarters is located in Cambridge, MA, and we have a significant and growing site in Boulder, CO.
What does beam therapeutics do?
Beam is pioneering the use of base editing — a potential new class of precision genetic medicines — with a vision of providing life-long cures to patients suffering from serious diseases.
Is Editas Medicine a buy right now?
What stocks does MarketBeat like better than Editas Medicine?
14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 sell ratings, 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Editas Medicine stock.
When is Editas Medicine's next earnings date?
Wall Street analysts have given Editas Medicine a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Editas Medicine wasn't one of them.
How were Editas Medicine's earnings last quarter?
Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Editas Medicine.
How has Editas Medicine's stock been impacted by Coronavirus?
Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. The company earned $0.38 million during the quarter, compared to analysts' expectations of $6.78 million.
What price target have analysts set for EDIT?
Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EDIT stock has increased by 238.5% and is now trading at $68.61.#N#View which stocks have been most impacted by COVID-19.
Who are some of Editas Medicine's key competitors?
14 analysts have issued 1-year target prices for Editas Medicine's stock. Their forecasts range from $14.00 to $86.00. On average, they anticipate Editas Medicine's share price to reach $54.86 in the next twelve months.
Editas Medicine Media Sentiment
Some companies that are related to Editas Medicine include Novozymes A/S (NVZMY), argenx (ARGX), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Acceleron Pharma (XLRN), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Exelixis (EXEL), Halozyme Therapeutics (HALO), Twist Bioscience (TWST) and Adaptive Biotechnologies (ADPT).#N#View all of EDIT's competitors..
Media Coverage
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Editas Medicine (NASDAQ EDIT) News Headlines Today
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
EDIT Target Price
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
Editas Medicine Inc ( EDIT ) Stock Market info
EDIT price target in 14 days: 71.002 USD* upside and 62.290 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Editas Medicine Inc ( EDIT ) Stock Price Prediction, Stock Forecast for next months and years
Recommendations: Buy or sell Editas Medicine stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.
Editas Medicine, Inc. (EDIT)
Below you will find the price predictions for 2021, 2022, 2023, 2024, 2025, 2026.
Editas Medicine, Inc. - Hold
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Chart for EDIT
Zacks' proprietary data indicates that Editas Medicine, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the EDIT shares relative to the market in the next few months. In addition, Editas Medicine, Inc.
Here are some best guesses about the biotech stock's huge jump
Cambridge, MA-based Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology.
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Editas Medicine ( NASDAQ:EDIT) were skyrocketing 41.5% higher as of 11:57 a.m. EST on Monday. The company didn't announce any big news over the weekend or today, so why is the stock taking off?
Now what
Huge jumps like Editas is delivering today are exciting. However, investors probably shouldn't become overly exuberant. Sometimes stocks can go down even more quickly than they go up.
